These data collectively suggest that, among the three biomarkers, dynamic changes in WFDC2, alongside sPD-1 and sPD-L1 (to a lesser extent), are significantly associated with tumor response and survival outcomes during anti-PD-1 therapy. Here, HOXD13 is linked to neoplasm.